6959-02-0Relevant articles and documents
Designing of a Magnetodielectric System in Hybrid Organic–Inorganic Framework, a Perovskite Layered Phosphonate MnO3PC6H4-m-Br?H2O
Basu, Tathamay,Bloyet, Clarisse,Beaubras, Félicien,Caignaert, Vincent,Perez, Olivier,Rueff, Jean-Michel,Pautrat, Alain,Raveau, Bernard,Lohier, Jean-Fran?ois,Jaffrès, Paul-Alain,Couthon, Hélène,Rogez, Guillaume,Taupier, Grégory,Dorkenoo, Honorat
, (2019/06/24)
Very few hybrid organic–inorganic framework (HOIF) exhibit direct coupling between spins and dipoles and are also restricted to a particular COOH-based system. It is shown how one can design a hybrid system to obtain such coupling based on the rational design of the organic ligands. The layered phosphonate, MnO3PC6H5?H2O, consisting of perovskite layers stacked with organic phenyl layers, is used as a starting potential candidate. To introduce dipole moment, a closely related metal phosphonate, MnO3PC6H4-m-Br?H2O is designed. For this purpose, this phosphonate is prepared from 3-bromophenylphosphonic acid that features one electronegative bromine atom directly attached on the aromatic ring in the meta position, lowering the symmetry of precursor itself. Thus, bromobenzene moieties in MnO3PC6H4-m-Br?H2O induce a finite dipole moment. This new designed compound exhibits complex magnetism, as observed in layered alkyl chains MnO3PCnH2 n +1?H2O materials, namely, 2D magnetic ordering ≈20 K followed by weak ferromagnetic ordering below 12 K (T1) with a magnetic field (H)-induced transition ≈25 kOe below T1. All these magnetic features are exactly captured in the T and H-dependent dielectric constant, ε′(T) and ε′(H). This demonstrates direct magnetodielectric coupling in this designed hybrid and yields a new path to tune multiferroic ordering and magnetodielectric coupling.
Thrombopoietin mimetics
-
Page 42, (2008/06/13)
Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative.